Sudbury Living
Sudbury Living PDF Editions Sudbury Feature Publications Sudbury Living Weddings PDF Editions

Zulich purchases landmark watertower

Sudbury Living Magazine July 27, 2016 Upfront No Comments on Zulich purchases landmark watertower




In efforts to advance treatment for ALS and to sustain one of Sudbury’s most visible landmarks, Dario Zulich has purchased the Sudbury water tower.

The CEO of TESC Contracting Company Ltd. and partner with his family in Zulich Enterprises included an $80,000
donation to the Adaptive Canuck ALS Foundation as part of the purchase agreement, to be used
towards ALS adult stem cell investigation in Canada.
Local entrepreneurs, Jeff Perreault and Justin Roy of Media Environmental, purchased the water tower
in 2010 with plans for major development. However, in 2014 at just 32 years old, Perreault was
diagnosed with ALS, forcing him to take a step back from his business ventures and concentrate on
his health.

Perreault and wife Brittney then founded a charity, the ‘Adaptive Canuck ALS Foundation’,
where its goal is to fund and accelerate the development of a unique cellular replacement treatment
that restores health and motor functions for patients with ALS, prevents progression of the disease,
and potentially offers a cure.
As a strong supporter of downtown beautification, Zulich wanted to preserve the water tower and
ensure that the prominent landmark did not deteriorate. With the objective to maintain a pleasant
community appearance to help attract business investment, tourism and residents, Zulich decided to
acquire the water tower. Additionally, since Zulich’s first point of contact with Perreault several years
ago, the two businessmen developed a friendship, and in the end, Zulich aspired to help his longtime
“The Sudbury water tower is a well-known symbol in our community, and I am committed to its
preservation,” said Zulich. “I will make every attempt to honour Jeff’s wish for future
development, as the tower and property have great potential. But most importantly, I am pleased
that this purchase can enlighten efforts with ALS stem cell research. I hope that my donation will
provide some assistance to this remarkable cause.”
Zulich’s financial contribution helps solidify the foundation’s fundraising target of $400,000 for phase
2 of 3 of the ALS stem research project in Toronto. Currently, there is no cure or treatment for ALS.
Phase 2 consists of a pre-clinical evaluation in ALS mice models, where a team of doctors and scientists
study how the transplanted cells function and determine if they can restore function.

Scientists are also validating the best source of stem cells for potential human clinical trial beginning in 2017.
In phase 3, $1.5M is required to host Canada’s first ever pilot clinical trial in ALS patients where the
efficacy and safety of the new therapy will be evaluated. If successful, this therapy will accelerate its
introduction into clinical practice and will improve care and health outcomes for ALS patients.
“I am relieved that the water tower is in good hands with a community builder like Dario”, said Jeff Perreault.

“I trust that whatever he chooses to do with it will beautify Greater Sudbury and instill additional investment in our community. Furthermore, I am extremely grateful for Dario’s very generous contribution to ALS adult stem cell research. For myself, my family and all the other families and patients living and suffering from this debilitating disease, it is truly a monumental gift!”

About Adaptive Canuck ALS Foundation

Adaptive Canucks ALS Foundation was created as a non-profit organization in 2014 and became a Canadian Registered Charity in 2016 (charitable registration no. 82713 7589 RR0001). The charity is managed by Canadian families living with amyotrophic lateral sclerosis (ALS or Lou Gehrig’s Disease), who It lead, build teams, fund research, and work towards a cure. Adaptive Canuck ALS Foundation was founded with an unbreakable commitment towards supporting and advancing ALS stem cell research that leads to accelerated approval for human treatment to Canadian PALS (Patient diagnosed with ALS).

source: press release

Like this Article? Share it!

About The Author

Leave A Response